Cangrelor in critically ill patients with cardiogenic shock or post-cardiac arrest undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Hendrianus Hendrianus, Young-Hoon Jeong, Sang Yeub Lee, Jun Hwan Cho, Jinhwan Jo, Diana A Gorog, Jacek Kubica, Udaya S Tantry, Paul A Gurbel, Sang-Wook Kim · 2025
Read Cangrelor in critically ill patients with cardiogenic shock or post-cardiac arrest undergoing percutaneous coronary intervention: a systematic review and meta-analysis by Hendrianus Hendrianus, Young-Hoon Jeong, Sang Yeub Lee, Jun Hwan Cho, Jinhwan Jo, Diana A Gorog, Jacek Kubica, Udaya S Tantry, Paul A Gurbel, Sang-Wook Kim (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12860006.txt.
Description
Hendrianus Hendrianus and nine co-authors pool the evidence on a fast blood-thinning drug for the sickest heart patients, in a 2025 review. Cangrelor is given by vein and blocks platelets within minutes, unlike pills that absorb slowly in a shocked body. The patients in question have cardiogenic shock or have just been resuscitated, and all undergo stenting. Evidence for this group was extremely thin. The authors searched three databases for studies comparing the drug against standard oral therapy.
Outcomes pooled include death from any cause, heart death, stent clots, heart attack, stroke, and blood flow grades. The synthesis, registered in advance, gives intensive care and cath lab teams a firmer basis for a drug choice they currently make on habit and hope.
Catalog record
| CREATOR | Hendrianus Hendrianus, Young-Hoon Jeong, Sang Yeub Lee, Jun Hwan Cho, Jinhwan Jo, Diana A Gorog, Jacek Kubica, Udaya S Tantry, Paul A Gurbel, Sang-Wook Kim |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |